Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Table 2 Key response results

Parameter	HL patients	ALCL patients
	(N = 20)	(N = 8)
Objective response rate (CR + PR)	12 (60)	7 (88)
Best clinical response^a
Complete remission	6 (30)	5 (63)
Partial remission	6 (30)	2 (25)
Stable disease	4 (20)	0
Progressive disease	4 (20)	1 (13)
95% CI for ORR^b	36.1, 80.9	47.3, 99.7
95% CI for CR rate^b	11.9, 54.3	24.5, 91.5
Duration of objective response for patients with OR, months^c	12 (60)	7 (88)
Median (95% CI)^d	9.2 (2.1, -)	12.3 (6.6, -)
Duration of response for patients with CR, months^c	6 (30)	5 (63)
Median (95% CI)^d	9.4 (1.7, 14.2)	12.9 (7.4, -)
Progression-free survival, months^e
Median (95% CI)^d	9.9 (3.4, 13.4)	12.9 (1.4, 18.5)
Overall survival, months^e
Median (95% CI)^d	- (11.4, -)	- (3.3, -)

Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.
^aBest response (according to Cheson 2007) prior to the start of any new antitumor treatment, exclusive of stem cell transplant.
^bTwo-sided 95% exact confidence interval (CI), computed using the Clopper-Pearson method (1934).
^cDuration of response is calculated from the earliest occurrence of either complete or partial remission.
^dComputed using the log-log transformation method of Collett (1994).
e As estimated using Kaplan-Meier methods.

ISSN: 1756-8722